Novavax has said its protein-based COVID-19 vaccine product produced an efficacy rate of 89.3 per cent in late stage clinical trials, with strong protection against the strain of the virus first reported in the U.K., which has shown to be more resistant to other vaccine candidates.Ĭanada agreed to purchase shots from Novavax - a biotechnology company that has been at the forefront of developing new vaccines against influenza - last August. Novavax vaccine is effective against UK variant The first Canadian-made Novavax vials won't be produced until the end of the year, the government said, well after the prime minister has promised every Canadian would be inoculated against COVID-19. The Novavax product has to be approved by Health Canada regulators, the NRC has to finish building the plant itself and the facility has to be certified to make the vaccines all of which is expected to take months to complete. The agreement will help jump start Canada's largely dormant domestic vaccine manufacturing industry but it will do little to meet the short-term demand for COVID-19 vaccines. "We won't rest until every Canadian who wants a vaccine has received one." We need as much domestic capacity for vaccine production as possible," Trudeau said. "This is a major step forward to get vaccines made in Canada, for Canadians. The National Research Council-owned Royalmount facility will churn out tens of millions of doses of the product developed by Maryland-based Novavax, Trudeau said. That company submitted its vaccine to Health Canada for regulatory approval last Friday. Prime Minister Justin Trudeau announced today a plan to produce millions of COVID-19 shots at a plant in Montreal starting later this year, securing a domestic supply of vaccines as the global market contends with delivery delays and protectionist measures.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |